<p>CRISPR 治疗公司（NASDAQ:CRSP - 获取免费报告）的股票在 Needham &amp; Company LLC 发布给客户和投资者的研究报告中被投资分析师重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 84.00 美元。Needham &amp; Company LLC 的目标价暗示该公司股价有 66.80% 的潜在上涨空间。</p>
<p>获取 <strong>CRISPR 治疗公司</strong> 的提醒：</p>
<ul>
<li>3 只被压制的制药股，具备上涨催化剂</li>
</ul>
<p>其他几位股票研究分析师也最近对 CRSP 发表了评论。Rodman &amp; Renshaw 在 8 月 2 日（星期五）的一份研究报告中开始覆盖 CRISPR 治疗公司的股票。他们设定了 “买入” 评级和 90.00 美元的目标价。StockNews.com 在 10 月 29 日（星期二）的一份研究报告中将 CRISPR 治疗公司的股票评级上调至 “卖出”。加拿大皇家银行在 10 月 4 日（星期五）的一份研究报告中将 CRISPR 治疗公司的目标价从 60.00 美元下调至 53.00 美元，并设定了 “行业表现” 评级。巴克莱在 8 月 6 日（星期二）的一份研究报告中将 CRISPR 治疗公司的目标价从 67.00 美元下调至 59.00 美元，并为该公司设定了 “等权重” 评级。最后，Chardan Capital 在 8 月 6 日（星期二）的一份报告中将 CRISPR 治疗公司的目标价从 112.00 美元下调至 94.00 美元，并设定了 “买入” 评级。三位研究分析师对该股票给予了 “卖出” 评级，八位给予了 “持有” 评级，九位给予了 “买入” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价为 75.19 美元。</p>
<p><strong>查看我们对 CRISPR 治疗公司的最新股票分析</strong></p>
<h2>CRISPR 治疗公司股票表现</h2>
<ul>
<li>Geron 股票在 Imetelstat 获得 FDA 小组批准后翻倍</li>
</ul>
<p>CRSP 股票在星期三开盘价为 50.36 美元。该股票的 50 日移动平均线为 47.22 美元，200 日移动平均线为 52.25 美元。CRISPR 治疗公司的 52 周低点为 43.42 美元，52 周高点为 91.10 美元。该股票的市值为 42.8 亿美元，市盈率为-15.59，贝塔值为 1.67。</p>
<p>CRISPR 治疗公司（NASDAQ:CRSP - 获取免费报告）最近在 11 月 5 日（星期二）发布了其财报。该公司报告本季度每股收益（EPS）为-1.01 美元，超出市场共识预期的-1.42 美元 0.41 美元。该公司在本季度的收入为 60 万美元，而市场共识预期为 665 万美元。去年同期，该公司的每股收益为-1.41 美元。分析师预计 CRISPR 治疗公司在当前财年将发布-5.57 美元的每股收益。</p>
<h2>CRISPR 治疗公司的内部交易</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
<p>在相关消息中，首席法律顾问 James R. Kasinger 在 10 月 14 日（星期一）出售了 1,089 股该股票。股份以 46.28 美元的平均价格出售，总交易额为 50,398.92 美元。交易后，首席法律顾问现在直接持有 62,597 股公司股票，价值 2,896,989.16 美元。这代表其持股比例下降了 0.00%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。在其他 CRISPR 治疗公司的新闻中，首席执行官 Samarth Kulkarni 在 10 月 14 日（星期一）出售了 4,293 股公司的股票。股份以 46.28 美元的平均价格出售，总交易额为 198,680.04 美元。交易后，首席执行官现在持有 226,540 股公司股票，价值约 10,484,271.20 美元。这代表其持股比例下降了 0.00%。该交易在与 SEC 的文件中披露，相关信息可通过此链接访问。此外，首席法律顾问 James R. Kasinger 在 10 月 14 日（星期一）出售了 1,089 股 CRISPR 治疗公司的股票。股份以 46.28 美元的平均价格出售，总交易额为 50,398.92 美元。交易后，首席法律顾问现在持有 62,597 股公司股票，价值 2,896,989.16 美元。这代表其持股比例下降了 0.00%。该出售的披露信息可在此处找到。内部人士持有公司股票的 4.10%。</p>
<h2>CRISPR 治疗公司的机构交易</h2>
<p>几家机构投资者和对冲基金最近调整了对该股票的持有。SFE 投资顾问在第二季度增持了 CRISPR 治疗公司的股份，增幅为 3.6%。SFE 投资顾问现在持有 5,846 股公司股票，价值 316,000 美元，此前在上个季度增持了 203 股。西北互助财富管理公司在第二季度增持了 CRISPR 治疗公司的股份，增幅为 4.8%。西北互助财富管理公司现在持有 4,606 股公司股票，价值 249,000 美元，此前在上个季度增持了 211 股。Orion 资本管理公司在第一季度增持了 CRISPR 治疗公司的股份，增幅为 44.0%。Orion 资本管理公司现在持有 720 股公司股票，价值 49,000 美元，此前在上个季度增持了 220 股。加拿大国家银行 FI 在第二季度增持了 CRISPR 治疗公司的股份，增幅为 35.0%。加拿大国家银行 FI 现在持有 848 股公司股票，价值 46,000 美元，此前在该期间增持了 220 股。最后，Larson 金融集团在第二季度增持了 CRISPR 治疗公司的股份，增幅为 95.5%。Larson 金融集团现在持有 565 股公司股票，价值 31,000 美元，此前在上个季度增持了 276 股。69.20% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>CRISPR 治疗公司简介</h2>
<p>（获取免费报告）</p>
<p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发针对严重疾病的变革性基因药物。CRISPR/Cas9 是一项革命性的基因编辑技术，能够对基因组 DNA 进行精确、定向的修改。CRISPR Therapeutics 已经建立了一个涵盖多种疾病领域的治疗项目组合，包括血红蛋白病、肿瘤学、再生医学和罕见疾病。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>如何计算通货膨胀率</li>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>Hims &amp; Hers：为什么这只医疗股票的增长使其成为买入对象</li>
<li>期权交易 - 理解行使价格</li>
<li>Astera Labs 的股票大幅上涨：这种增长能否持续？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ Tim Sykes 的紧急交易提醒：“立即采取此行动”（来自 Timothy Sykes）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA"/></p>
<h2>你现在应该投资 1000 美元在 CRISPR Therapeutics 吗？</h2>
<p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 CRISPR Therapeutics 并不在名单上。</p>
<p>虽然 CRISPR Therapeutics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CRISPR治疗

<p>Needham & Company LLC 重申了对 CRISPR Therapeutics (NASDAQ:CRSP) 的 “买入” 评级，目标价暗示潜在上涨幅度为 66.80%。该股票目前在分析师中获得了混合评级，其中包括三项卖出评级、八项持有评级和九项买入评级。CRISPR Therapeutics 报告每股收益为 -$0.01，超出预期，市值为 12.8 亿美元。最近的内部交易包括首席执行官和总法律顾问的股票出售。该股票开盘价为 $6.36，52 周范围为 $4.42 至 $10.10</p>

<p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its &#34;buy&#34; rating restated by investment analysts at Needham &amp; Company LLC in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $84.00 price objective on the stock. Needham &amp; Company LLC's target price would suggest a potential upside of 66.80% from the company's previous close.</p>
<div class="lb-trans"><p>CRISPR 治疗公司（NASDAQ:CRSP - 获取免费报告）的股票在 Needham &amp; Company LLC 发布给客户和投资者的研究报告中被投资分析师重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 84.00 美元。Needham &amp; Company LLC 的目标价暗示该公司股价有 66.80% 的潜在上涨空间。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CRISPR 治疗公司</strong> 的提醒：</p>
</div><ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被压制的制药股，具备上涨催化剂</li>
</ul>
</div><p>Several other equities research analysts have also recently commented on CRSP. Rodman &amp; Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a &#34;buy&#34; rating and a $90.00 price target on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a &#34;sell&#34; rating in a research note on Tuesday, October 29th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $60.00 to $53.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Friday, October 4th. Barclays cut their price objective on CRISPR Therapeutics from $67.00 to $59.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, August 6th. Finally, Chardan Capital decreased their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and an average price target of $75.19.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对 CRSP 发表了评论。Rodman &amp; Renshaw 在 8 月 2 日（星期五）的一份研究报告中开始覆盖 CRISPR 治疗公司的股票。他们设定了 “买入” 评级和 90.00 美元的目标价。StockNews.com 在 10 月 29 日（星期二）的一份研究报告中将 CRISPR 治疗公司的股票评级上调至 “卖出”。加拿大皇家银行在 10 月 4 日（星期五）的一份研究报告中将 CRISPR 治疗公司的目标价从 60.00 美元下调至 53.00 美元，并设定了 “行业表现” 评级。巴克莱在 8 月 6 日（星期二）的一份研究报告中将 CRISPR 治疗公司的目标价从 67.00 美元下调至 59.00 美元，并为该公司设定了 “等权重” 评级。最后，Chardan Capital 在 8 月 6 日（星期二）的一份报告中将 CRISPR 治疗公司的目标价从 112.00 美元下调至 94.00 美元，并设定了 “买入” 评级。三位研究分析师对该股票给予了 “卖出” 评级，八位给予了 “持有” 评级，九位给予了 “买入” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价为 75.19 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on CRISPR Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CRISPR 治疗公司的最新股票分析</strong></p>
</div><h2>CRISPR Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>CRISPR 治疗公司股票表现</h2>
</div><ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><ul>
<li>Geron 股票在 Imetelstat 获得 FDA 小组批准后翻倍</li>
</ul>
</div><p>Shares of CRSP stock opened at $50.36 on Wednesday. The stock's fifty day moving average is $47.22 and its 200-day moving average is $52.25. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10. The stock has a market capitalization of $4.28 billion, a PE ratio of -15.59 and a beta of 1.67.</p>
<div class="lb-trans"><p>CRSP 股票在星期三开盘价为 50.36 美元。该股票的 50 日移动平均线为 47.22 美元，200 日移动平均线为 52.25 美元。CRISPR 治疗公司的 52 周低点为 43.42 美元，52 周高点为 91.10 美元。该股票的市值为 42.8 亿美元，市盈率为-15.59，贝塔值为 1.67。</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period last year, the business posted ($1.41) EPS. As a group, analysts forecast that CRISPR Therapeutics will post -5.57 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>CRISPR 治疗公司（NASDAQ:CRSP - 获取免费报告）最近在 11 月 5 日（星期二）发布了其财报。该公司报告本季度每股收益（EPS）为-1.01 美元，超出市场共识预期的-1.42 美元 0.41 美元。该公司在本季度的收入为 60 万美元，而市场共识预期为 665 万美元。去年同期，该公司的每股收益为-1.41 美元。分析师预计 CRISPR 治疗公司在当前财年将发布-5.57 美元的每股收益。</p>
</div><h2>Insider Transactions at CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR 治疗公司的内部交易</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
</div><p>In related news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company's stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company's stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席法律顾问 James R. Kasinger 在 10 月 14 日（星期一）出售了 1,089 股该股票。股份以 46.28 美元的平均价格出售，总交易额为 50,398.92 美元。交易后，首席法律顾问现在直接持有 62,597 股公司股票，价值 2,896,989.16 美元。这代表其持股比例下降了 0.00%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。在其他 CRISPR 治疗公司的新闻中，首席执行官 Samarth Kulkarni 在 10 月 14 日（星期一）出售了 4,293 股公司的股票。股份以 46.28 美元的平均价格出售，总交易额为 198,680.04 美元。交易后，首席执行官现在持有 226,540 股公司股票，价值约 10,484,271.20 美元。这代表其持股比例下降了 0.00%。该交易在与 SEC 的文件中披露，相关信息可通过此链接访问。此外，首席法律顾问 James R. Kasinger 在 10 月 14 日（星期一）出售了 1,089 股 CRISPR 治疗公司的股票。股份以 46.28 美元的平均价格出售，总交易额为 50,398.92 美元。交易后，首席法律顾问现在持有 62,597 股公司股票，价值 2,896,989.16 美元。这代表其持股比例下降了 0.00%。该出售的披露信息可在此处找到。内部人士持有公司股票的 4.10%。</p>
</div><h2>Institutional Trading of CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR 治疗公司的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of the stock. SFE Investment Counsel boosted its holdings in CRISPR Therapeutics by 3.6% during the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company's stock worth $316,000 after acquiring an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock valued at $249,000 after acquiring an additional 211 shares in the last quarter. Orion Capital Management LLC boosted its position in CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company's stock worth $49,000 after purchasing an additional 220 shares during the last quarter. National Bank of Canada FI raised its stake in shares of CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after purchasing an additional 220 shares during the period. Finally, Larson Financial Group LLC increased its holdings in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock worth $31,000 after buying an additional 276 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近调整了对该股票的持有。SFE 投资顾问在第二季度增持了 CRISPR 治疗公司的股份，增幅为 3.6%。SFE 投资顾问现在持有 5,846 股公司股票，价值 316,000 美元，此前在上个季度增持了 203 股。西北互助财富管理公司在第二季度增持了 CRISPR 治疗公司的股份，增幅为 4.8%。西北互助财富管理公司现在持有 4,606 股公司股票，价值 249,000 美元，此前在上个季度增持了 211 股。Orion 资本管理公司在第一季度增持了 CRISPR 治疗公司的股份，增幅为 44.0%。Orion 资本管理公司现在持有 720 股公司股票，价值 49,000 美元，此前在上个季度增持了 220 股。加拿大国家银行 FI 在第二季度增持了 CRISPR 治疗公司的股份，增幅为 35.0%。加拿大国家银行 FI 现在持有 848 股公司股票，价值 46,000 美元，此前在该期间增持了 220 股。最后，Larson 金融集团在第二季度增持了 CRISPR 治疗公司的股份，增幅为 95.5%。Larson 金融集团现在持有 565 股公司股票，价值 31,000 美元，此前在上个季度增持了 276 股。69.20% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>CRISPR Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>CRISPR 治疗公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家基因编辑公司，专注于利用其专有的 CRISPR/Cas9 平台开发针对严重疾病的变革性基因药物。CRISPR/Cas9 是一项革命性的基因编辑技术，能够对基因组 DNA 进行精确、定向的修改。CRISPR Therapeutics 已经建立了一个涵盖多种疾病领域的治疗项目组合，包括血红蛋白病、肿瘤学、再生医学和罕见疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>How to Calculate Inflation Rate</li>
<li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Hims &amp; Hers: Why This Healthcare Stock’s Growth Makes It a Buy</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Astera Labs’ Big Stock Jump: Can the Growth Be Sustained?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 CRISPR Therapeutics 更好的股票</li>
<li>如何计算通货膨胀率</li>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>Hims &amp; Hers：为什么这只医疗股票的增长使其成为买入对象</li>
<li>期权交易 - 理解行使价格</li>
<li>Astera Labs 的股票大幅上涨：这种增长能否持续？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ Tim Sykes 的紧急交易提醒：“立即采取此行动”（来自 Timothy Sykes）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10158&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in CRISPR Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 CRISPR Therapeutics 吗？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CRISPR Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 CRISPR Therapeutics 并不在名单上。</p>
</div><p>While CRISPR Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CRISPR Therapeutics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Needham & Company LLC 重申对 CRISPR 治疗（NASDAQ:CRSP）的买入评级